COI: Alive and Thriving at the NEJM by David J. Elpern, M.D. Abstract: As a reader of the New England Journal of Medicine for more than 50 years, I have observed its growing entanglements with the pharmaceutical industry.  This analysis of a recent NEJM research article highlights authorial and editorial conflicts of interest (COI) and discusses how the Journal benefits financially from pharmaceutical advertisements for the very drug reported on in the Original Article.  What does this say about top tier medical publishing when the world’s most prestigious medical journal is clearly intertwined with the drug industry? The December 3, 2020 issue of the New England Journal of Medicine (NEJM), … Continue reading →